{
  "slug": "chronic-kidney-disease",
  "title": {
    "zh": "慢性腎病：亞洲管線與全球對手",
    "en": "Chronic kidney disease: Asian pipelines and global competitors"
  },
  "answer": {
    "zh": "截至 2026-11-14，亞洲慢性腎病管線涵蓋向榮生技的 ELIXCYTE-CKD 細胞療法，以及聚焦 IgA 腎病的大塚 sibeprenlimab 與雲頂新耀 NEFECON。全球對手包括研究中的 balcinrenone／dapagliflozin 組合與 finerenone。IgA 腎病、糖尿病腎病與廣義慢性腎病的族群不同，表內分列適應症與核准狀態。",
    "en": "As of 2026-11-14, Asian CKD programs include UnicoCell’s ELIXCYTE-CKD cell therapy and the IgA-nephropathy products sibeprenlimab from Otsuka and NEFECON from Everest Medicines. Global comparators include investigational balcinrenone/dapagliflozin and finerenone. IgA nephropathy, diabetic kidney disease and broader CKD are distinct populations; indications and approval status are separated below."
  },
  "scope": {
    "zh": "選列腎功能保護與疾病修飾路徑；未完整收錄 ACEi／ARB、SGLT2 抑制劑單方與透析併發症藥物。",
    "en": "Selected kidney-protection and disease-modifying approaches; ACE inhibitors, ARBs, SGLT2 monotherapies and dialysis-complication medicines are not exhaustively covered."
  },
  "as_of": "2026-11-14",
  "window_start": "2026-08-17",
  "window_end": "2026-11-14",
  "rows": [
    {
      "id": "ckd-unicocell",
      "company": {
        "zh": "向榮生技（台灣）",
        "en": "UnicoCell (Taiwan)"
      },
      "asset": "ELIXCYTE-CKD",
      "asia": true,
      "mechanism": {
        "zh": "異體脂肪來源間質幹細胞",
        "en": "Allogeneic adipose-derived mesenchymal stromal cells"
      },
      "stage": {
        "zh": "第一／二期完成；第三期 IND 已申請",
        "en": "Phase 1/2 completed; Phase 3 IND submitted"
      },
      "indication": {
        "zh": "慢性腎病",
        "en": "Chronic kidney disease"
      },
      "route": {
        "zh": "靜脈",
        "en": "IV"
      },
      "latest": {
        "zh": "10-01 公告提及持續推進 CKD 管線；細胞出口許可是另一事項，非 CKD 藥證。",
        "en": "The 10-01 release confirms continued CKD development; its cell export license is a separate matter, not CKD marketing approval."
      },
      "date": "2026-10-01",
      "sources": [
        {
          "url": "https://www.unicocell.com/en/website/news/detail/414",
          "title": "UnicoCell October update",
          "date": "2026-10-01",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://www.unicocell.com/en/website/news/detail/404",
          "title": "UnicoCell CKD Phase 1/2 publication and IND",
          "date": "2026-02-06",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ckd-otsuka",
      "company": {
        "zh": "大塚／Visterra",
        "en": "Otsuka / Visterra"
      },
      "asset": "sibeprenlimab / VOYXACT",
      "asia": true,
      "mechanism": {
        "zh": "抗 APRIL 抗體",
        "en": "Anti-APRIL antibody"
      },
      "stage": {
        "zh": "美國加速核准；確認性資料已報告",
        "en": "US accelerated approval; confirmatory data reported"
      },
      "indication": {
        "zh": "有進展風險的成人原發性 IgA 腎病",
        "en": "Adults with primary IgA nephropathy at risk of progression"
      },
      "route": {
        "zh": "皮下",
        "en": "SC"
      },
      "latest": {
        "zh": "於 ASN 公布 VISIONARY 第三期最終兩年結果；加速核准與最終資料分開記錄。",
        "en": "Presented final two-year Phase 3 VISIONARY results at ASN; accelerated approval and final data are separate milestones."
      },
      "date": "2026-10-23",
      "sources": [
        {
          "url": "https://www.otsuka.co.jp/en/company/newsreleases/2026/20261023_1.html",
          "title": "Otsuka VISIONARY final results",
          "date": "2026-10-23",
          "accessed_at": "2026-11-15"
        },
        {
          "url": "https://www.otsuka.co.jp/en/company/newsreleases/2025/20251126_1.html",
          "title": "Otsuka FDA accelerated approval",
          "date": "2025-11-26",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ckd-everest",
      "company": {
        "zh": "雲頂新耀；原研 Calliditas",
        "en": "Everest Medicines; originated by Calliditas"
      },
      "asset": "NEFECON / targeted-release budesonide",
      "asia": true,
      "mechanism": {
        "zh": "迴腸靶向釋放 budesonide",
        "en": "Ileum-targeted release budesonide"
      },
      "stage": {
        "zh": "中國已完全核准",
        "en": "Full approval in China"
      },
      "indication": {
        "zh": "原發性 IgA 腎病",
        "en": "Primary IgA nephropathy"
      },
      "route": {
        "zh": "口服",
        "en": "Oral"
      },
      "latest": {
        "zh": "公司產品頁記載 2025-04 中國完全核准；該頁未提供本產品更晚的具日期里程碑。",
        "en": "The product page records full China approval in 2025-04; no later dated milestone for this product is supplied on that page."
      },
      "date": "2025-04",
      "sources": [
        {
          "url": "https://everestmedicines.com/product-science/pipeline-and-major-products",
          "title": "Everest official product page",
          "date": null,
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "區域授權產品；本表未核交易金額",
        "en": "Regionally licensed product; deal amounts not verified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ckd-az",
      "company": {
        "zh": "阿斯特捷利康",
        "en": "AstraZeneca"
      },
      "asset": "balcinrenone / dapagliflozin",
      "asia": false,
      "mechanism": {
        "zh": "非類固醇 MRA／SGLT2 抑制",
        "en": "Non-steroidal MRA / SGLT2 inhibition"
      },
      "stage": {
        "zh": "第三期",
        "en": "Phase 3"
      },
      "indication": {
        "zh": "晚期慢性腎病；另有合併心衰竭項目",
        "en": "Advanced CKD; separate HF-with-CKD program"
      },
      "route": {
        "zh": "口服",
        "en": "Oral"
      },
      "latest": {
        "zh": "10-30 版官方管線列為第三期；這是管線快照，非當日新啟動試驗。",
        "en": "The 10-30 pipeline snapshot lists Phase 3; the snapshot is not evidence of trial initiation on that date."
      },
      "date": "2026-10-30",
      "sources": [
        {
          "url": "https://www.astrazeneca.com/our-therapy-areas/pipeline.html",
          "title": "AstraZeneca pipeline snapshot",
          "date": "2026-10-30",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    },
    {
      "id": "ckd-bayer",
      "company": {
        "zh": "拜耳",
        "en": "Bayer"
      },
      "asset": "finerenone / KERENDIA",
      "asia": false,
      "mechanism": {
        "zh": "非類固醇礦物皮質素受體拮抗劑",
        "en": "Non-steroidal mineralocorticoid receptor antagonist"
      },
      "stage": {
        "zh": "糖尿病相關 CKD 已核准；非糖尿病 CKD 申請已受理",
        "en": "Approved in diabetes-associated CKD; non-diabetic CKD sNDA accepted"
      },
      "indication": {
        "zh": "糖尿病／非糖尿病 CKD 分開",
        "en": "Diabetic / non-diabetic CKD considered separately"
      },
      "route": {
        "zh": "口服",
        "en": "Oral"
      },
      "latest": {
        "zh": "宣布 FDA 受理非糖尿病 CKD 補充申請；受理不等於核准。",
        "en": "Announced FDA acceptance of the non-diabetic CKD sNDA; acceptance is not approval."
      },
      "date": "2026-10-08",
      "sources": [
        {
          "url": "https://www.bayer.com/en-us/united-states/news-and-stories/2026/kerendia-for-chronic-kidney-disease",
          "title": "Bayer non-diabetic CKD sNDA acceptance",
          "date": "2026-10-09",
          "accessed_at": "2026-11-15"
        }
      ],
      "trials": "",
      "deal": {
        "zh": "查無已核實交易條款",
        "en": "No verified deal terms identified"
      },
      "history": false,
      "checked_at": "2026-11-14"
    }
  ]
}
